… retreatment with erlotinib is an option for patients with NSCLC who initially benefitted from
previous EGFR-TKI treatment … in EGFR exon 20 does not exclude response to TKI retreatment. …

… erlotinib retreatment is an option for EGFR mutated NSCLC with acquired resistance to
EGFR-TKI … Additional advanced NSCLC pts without a documented EGFR mutation who fulfill the …

… The data of 27 patients who experienced treatment failure from their initial use of EGFR-TKI …
, the patients were retreated with EGFR-TKI (gefitinib 250 mg qd or erlotinib 150 mg qd), and …

… switched to another EGFR-TKI (erlotinib) after gefitinib failure, the EGFR-TKI-free interval …
between gefitinib and erlotinib was associated with longer PFS after the initiation of erlotinib [23]…

… No statistical differences in PFS or OS were observed between gefitinib and erlotinib as
the 2 nd EGFR-TKI (PFS, P = 0.23 and OS, P = 0.052). The toxicities associated with the 2 nd …

… Three orally administered EGFR TKIs have been approved … TKIs gefitinib and erlotinib and
the second-generation TKI afatinib. Gefitinib and erlotinib are reversible EGFR TKIs, whereas …

… those cancers which recur after stopping EGFR-TKI would be sensitive to TKI retreatment. …
of TKI treatment (12), patients were considered eligible for this analysis if an EGFR mutation …

… erlotinib or gefitinib, and that treatment with gefitinib is associated with an increased frequency
of severe hepatotoxicity. Such information on the frequency of severe AEs according to …

… treatment arms in patients with EGFR exon 21 L858R mutation [15]. Among patients with
EGFR exon 19 deletions in our study, treatment … arm than the erlotinib arm. Similar to the …

… with NSCLC, but only erlotinib secured continued approval for … role of erlotinib and other
EGFR TKIs in the treatment of NSCLC… of the TKIs and the challenges associated with treatment, …